Arena Pharmaceuticals, Inc. (ARNA)

[eastunder]

It's just nice to see the word Cannabinoid coming from a real biopharmaceutical company trading on the nasdaq and not some fly by night OTC stock that suddenly pulls the word out of thin air because their business as an auto repair shop wasn't working out. ;)

I am skeptical that it would be, or become, anything like Sativex
but I am very curious to learn where this patent will take them, what it will bring into the pipeline, and what APD371 is really about.

APD371, an orally available agonist of the CB2 receptor, is an internally discovered investigational drug candidate Arena is exploring for several potential indications, including chronic pain. This compound is designed to be highly selective to provide pain relief without psychotropic effects and without the potential for dependence or abuse. Preclinical efficacy with APD371 has been shown in animal models of pain.